Active — Not RecruitingPhase 4

Immunogenicity and Clinical Efficacy of 20-valent Pneumococcal Conjugate Vaccine (PCV20) in Lymphoma Survivors After Treatment With Anti-CD20 Therapy

United States30 participantsStarted 2023-10-06

Plain-language summary

To compare the effects of a pneumococcal vaccine called PCV20 when given as a single dose versus a boosted regimen to patients who previously received anti-CD20 therapy as treatment for B cell lymphoma.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patients who have a history of non-Hodgkin B-cell lymphoma and whose disease has been in remission for at least 1 year.
✓. Patients who received any anti-CD20 therapy at any time during their treatment for B-cell lymphoma.
✓. Patients who are at least 18 years of age.
✓. Patients who can provide consent; no legal authorized representative will be able to provide consent on a patient's behalf.

Exclusion criteria

✕. Patients who have received cellular therapy, including chimeric antigen receptor T-cell therapy or any type of hematopoietic cell transplantation.
✕. Patients who have received PCV or pneumococcal polysaccharide vaccine within 5 years of screening for enrollment.
✕. Patients who are unable to attend follow-up appointments at designated times at MD Anderson.
✕. Any vulnerable population patient ((children, pregnant women, cognitively impaired adults, or prisoners)

What they're measuring

Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0

Timeframe: through study completion; an average of 1 year

Trial details

NCT IDNCT06049134

SponsorM.D. Anderson Cancer Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-12-01

View on ClinicalTrials.gov More Lymphoma trials